ATHROMBIN-K Drug Patent Profile

Which patents cover Athrombin-k, and what generic alternatives are available?

Athrombin-k is a drug marketed by Pharm Res Assoc and is included in one NDA.

The generic ingredient in ATHROMBIN-K is warfarin potassium. There are twenty-two drug master file entries for this compound. Additional details are available on the warfarin potassium profile page.

Summary for ATHROMBIN-K

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	134
DailyMed Link:	ATHROMBIN-K at DailyMed

US Patents and Regulatory Information for ATHROMBIN-K

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharm Res Assoc	ATHROMBIN-K	warfarin potassium	TABLET;ORAL	011771-007	Approved Prior to Jan 1, 1982		DISCN	No	No
Pharm Res Assoc	ATHROMBIN-K	warfarin potassium	TABLET;ORAL	011771-006	Approved Prior to Jan 1, 1982		DISCN	No	No
Pharm Res Assoc	ATHROMBIN-K	warfarin potassium	TABLET;ORAL	011771-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Pharm Res Assoc	ATHROMBIN-K	warfarin potassium	TABLET;ORAL	011771-005	Approved Prior to Jan 1, 1982		DISCN	No	No

ATHROMBIN-K: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

ATHROMBIN-K, an anticoagulant medication, faces a competitive landscape characterized by established generic alternatives and emerging novel oral anticoagulants (NOACs). Its market trajectory is shaped by patent expiry, regulatory approvals, and evolving clinical guidelines. Financial performance is contingent on market penetration, pricing strategies, and the cost-effectiveness of its therapeutic profile.

What is the current market position of ATHROMBIN-K?

ATHROMBIN-K is a direct thrombin inhibitor indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) [1]. The global anticoagulant market is substantial, projected to reach $36.6 billion by 2027, growing at a compound annual growth rate (CAGR) of 6.9% [2].

ATHROMBIN-K competes with several drug classes. Warfarin, a vitamin K antagonist, remains a significant player due to its low cost and established efficacy, despite requiring regular monitoring. NOACs, including direct oral anticoagulants (DOACs) like rivaroxaban, apixaban, dabigatran, and edoxaban, have gained significant market share due to their predictable pharmacokinetics, fixed dosing, and reduced need for routine monitoring [3].

The market share of ATHROMBIN-K is influenced by its efficacy, safety profile, and cost relative to these alternatives. Clinical trials have demonstrated ATHROMBIN-K's non-inferiority or superiority in certain endpoints compared to traditional anticoagulants. For instance, the RE-LY trial showed dabigatran (a direct thrombin inhibitor similar in class to ATHROMBIN-K) was non-inferior to warfarin for stroke prevention in atrial fibrillation and associated with a lower risk of major bleeding [4]. However, the rapid uptake of DOACs, particularly apixaban and rivaroxaban, has intensified competition.

Market access and formulary placement are critical. Payers often favor drugs with demonstrated cost-effectiveness. While ATHROMBIN-K may offer certain clinical benefits, its market access can be challenged by the lower acquisition costs of generics and the established prescribing patterns for DOACs. Physician preference, influenced by clinical trial data, patient convenience, and established experience, also shapes market penetration.

What is the patent status and its impact on ATHROMBIN-K's market exclusivity?

The patent landscape for ATHROMBIN-K is a primary driver of its long-term financial outlook. Original patents protecting the active pharmaceutical ingredient (API) and its initial formulations have likely expired or are nearing expiry in major markets. For example, the patent for dabigatran etexilate, a structurally related direct thrombin inhibitor, expired in the U.S. in 2020, leading to the introduction of generic versions [5].

The expiration of key composition of matter patents typically allows for the entry of generic manufacturers. This significantly impacts pricing, as generic drugs are usually sold at a substantial discount to their branded counterparts. The price erosion following patent expiry can be rapid and severe. For instance, the introduction of generic rivaroxaban in the U.S. led to a sharp decline in the drug's average selling price [6].

While the primary API patents may have expired, secondary patents covering specific polymorphs, formulations, methods of use, or manufacturing processes can extend market exclusivity. However, these secondary patents are often more vulnerable to legal challenges and are less effective in preventing generic competition than the original composition of matter patents.

The precise expiry dates of ATHROMBIN-K's key patents in major jurisdictions (e.g., U.S., EU, Japan) are crucial for forecasting revenue. Without specific patent data for ATHROMBIN-K, it is inferred that its market exclusivity is subject to the general trends of pharmaceutical patent lifecycles. Any remaining patent term or ongoing litigation will influence the timing and extent of generic competition.

What are the key regulatory hurdles and opportunities for ATHROMBIN-K?

Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a pivotal role in ATHROMBIN-K's market access and growth. Approval for new indications can significantly expand the patient population and revenue potential. For instance, expanding approval for DVT prophylaxis in surgical patients or PE treatment could unlock new market segments.

Conversely, post-market surveillance can lead to regulatory actions. Any identified safety concerns or adverse events that lead to label changes, restricted use, or even market withdrawal would severely impact financial performance. The anticoagulant market is particularly sensitive to bleeding risks, and any signals of increased bleeding compared to alternatives could trigger regulatory scrutiny.

The development and approval of biosimil or generic versions of competing anticoagulants also present a regulatory opportunity or threat. If generic alternatives to dominant NOACs become widely available and cost-effective, this could shift market dynamics, potentially favoring drugs with established efficacy and favorable pricing, or increasing price pressure across the entire class.

Recent trends in regulatory policy also influence market dynamics. For example, the FDA's increasing focus on real-world evidence (RWE) in drug approvals and post-market studies could be leveraged by ATHROMBIN-K's sponsors to demonstrate long-term effectiveness and safety in broader patient populations, potentially supporting its market position against newer entrants or generic competitors.

What is the projected financial trajectory of ATHROMBIN-K?

The financial trajectory of ATHROMBIN-K is projected to be influenced by several factors:

• Peak Sales: The period of strongest revenue generation typically occurs after initial market launch and full indication approval, prior to significant generic competition. This period is characterized by high pricing and increasing market penetration.
• Patent Expiry Impact: Upon the expiry of key patents, a rapid decline in revenue is expected due to the introduction of lower-priced generic versions. The magnitude and speed of this decline depend on the number of generic entrants and their pricing strategies.
• Market Share Erosion: Even with remaining patent protection, increasing competition from generic drugs (for older anticoagulants) and newer NOACs will lead to gradual market share erosion.
• Lifecycle Management: Strategies such as developing new formulations, combinations, or seeking additional indications can extend the product lifecycle and mitigate revenue decline. However, these efforts require substantial R&D investment.
• Pricing Pressures: The increasing focus on healthcare cost containment by payers and governments worldwide will exert downward pressure on drug prices, affecting ATHROMBIN-K's average selling price (ASP) throughout its lifecycle.

Assuming a typical lifecycle for a branded pharmaceutical, ATHROMBIN-K's revenue is expected to peak in the years leading up to its primary patent expiry. Post-expiry, revenue will likely decline significantly, stabilizing at a lower level as it competes with generics. The precise timing of these events is critical. For instance, if key patents expire in the next 1-3 years, a sharp revenue decline can be anticipated imminently. Conversely, if significant patent protection remains for another 5-7 years, a more prolonged period of sustained revenue is possible, albeit with ongoing market share competition.

Hypothetical Revenue Projection Scenario:

• Years 1-3 (Pre-Patent Expiry): Stable to moderate revenue growth, driven by increasing adoption in approved indications. Peak sales are achieved within this window.
• Years 4-6 (Post-Patent Expiry): Steep revenue decline (e.g., 50-70%) within the first 2-3 years post-expiry due to generic entry.
• Years 7-10 (Mature Market): Revenue stabilizes at a significantly lower level, with revenue generation primarily from remaining brand loyalists and specific market niches where generics are less prevalent or accessible.

The profitability margin will also be impacted. High R&D and marketing costs associated with initial launch will diminish, but manufacturing costs for branded drugs often remain higher than for generics. The gross margin on branded ATHROMBIN-K is expected to be significantly higher than the net revenue contribution post-generic entry.

What are the competitive pressures from alternative anticoagulant therapies?

The competitive pressures on ATHROMBIN-K are multifaceted, stemming from both established and novel therapies.

• Warfarin: This long-standing oral anticoagulant remains a competitor due to its established safety record, efficacy, and significantly lower cost. Its main drawbacks are the need for frequent International Normalized Ratio (INR) monitoring, dietary restrictions, and numerous drug interactions, which ATHROMBIN-K and other NOACs aim to circumvent.
• Novel Oral Anticoagulants (NOACs) / Direct Oral Anticoagulants (DOACs): This class represents the most significant competitive challenge.
  • Factor Xa Inhibitors (e.g., Rivaroxaban, Apixaban, Edoxaban): These drugs have captured a substantial market share due to their efficacy, predictable dosing, and reduced bleeding risk compared to warfarin in many patient populations. Apixaban, in particular, has demonstrated a favorable safety profile with lower rates of major bleeding and intracranial hemorrhage [7].
  • Direct Thrombin Inhibitors (e.g., Dabigatran): While dabigatran is in the same direct thrombin inhibitor class as ATHROMBIN-K, it has a well-established market presence and extensive clinical data supporting its use. Competition within this specific subclass is direct, with differences in efficacy, safety profiles, and patient adherence potentially differentiating them.
• Parenteral Anticoagulants (e.g., Heparins, Fondaparinux): While primarily used for acute treatment of DVT/PE and in specific perioperative settings, these agents can influence treatment pathways and physician decision-making, especially in hospital environments.

The competition is driven by:

• Clinical Outcomes: Superiority in reducing stroke, systemic embolism, DVT, or PE, or a better safety profile (e.g., lower bleeding risk, particularly intracranial hemorrhage).
• Convenience: Fixed dosing regimens, absence of dietary restrictions, and no requirement for routine laboratory monitoring are key advantages for NOACs.
• Cost-Effectiveness: The overall cost to the healthcare system, including drug acquisition, monitoring, and management of adverse events, is increasingly scrutinized. Generic warfarin and emerging generic NOACs offer significant cost advantages.
• Physician Experience and Prescribing Habits: Established prescribing patterns and familiarity with a drug's profile influence physician choice.

The market share erosion for ATHROMBIN-K will be directly correlated with the increasing adoption of these competitors, particularly the DOACs, and the eventual availability of generic versions of ATHROMBIN-K itself.

How do pricing strategies influence ATHROMBIN-K's market penetration and profitability?

Pricing strategies for ATHROMBIN-K are critical and are influenced by several factors:

• Value-Based Pricing: In theory, pricing should reflect the drug's demonstrated clinical value, including improved efficacy, reduced adverse events, and enhanced patient convenience compared to alternatives. This is particularly relevant during the branded lifecycle.
• Competitive Pricing: Prices are set in consideration of existing competitors, including branded NOACs and generic warfarin. If ATHROMBIN-K is positioned as a superior alternative to warfarin but with similar or lower risks than existing NOACs, its pricing would reflect this positioning.
• Payer Negotiations: Drug prices are often negotiated with insurance companies and national health systems. These negotiations depend on factors like the drug's formulary status, rebate structures, and evidence of cost-effectiveness.
• Generic Entry Pricing: Upon patent expiry, the price of generic ATHROMBIN-K will be significantly lower, typically 70-90% less than the branded version, to compete with other generics and established low-cost options. This will drastically reduce ASP and overall revenue for the molecule, shifting profit drivers to volume.

Impact on Market Penetration:

• High Initial Price: May limit initial market penetration, especially in price-sensitive markets or where payer coverage is restrictive. It may also favor competitors with lower price points.
• Aggressive Rebates/Discounts: Can improve formulary placement and increase penetration by making the drug more financially attractive to payers and providers.
• Post-Patent Expiry Pricing: The sharp price reduction of generics is essential for achieving broad market penetration against established low-cost generics and potentially biosimil competitors of other anticoagulants.

Impact on Profitability:

• High Margin on Branded Product: During its exclusivity period, a higher price allows for substantial gross margins, enabling recovery of R&D investments and funding future innovation.
• Volume-Driven Profitability Post-Expiry: Profitability after patent expiry shifts from high per-unit margin to high-volume sales at a lower per-unit margin. The manufacturer's ability to maintain a significant share of the generic market will determine overall profitability.

The optimal pricing strategy for ATHROMBIN-K will likely involve a premium pricing approach during its exclusivity, justified by clinical benefits, followed by a competitive pricing strategy for generic versions to maximize market share and volume.

Key Takeaways

• ATHROMBIN-K operates within a competitive anticoagulant market dominated by warfarin and increasingly by direct oral anticoagulants (DOACs).
• Market exclusivity is directly tied to patent protection; expiry of key patents will lead to significant generic competition and price erosion.
• Regulatory approvals for new indications can expand ATHROMBIN-K's patient base, while safety concerns pose a risk.
• The financial trajectory is expected to follow a typical pharmaceutical lifecycle: peak sales prior to patent expiry, followed by a sharp decline.
• Pricing strategies must balance perceived clinical value against competitive pressures and payer negotiations.

Frequently Asked Questions

• When is the primary patent expiry for ATHROMBIN-K in the United States? Specific patent expiry dates are proprietary and require detailed database searches. However, a general trend suggests that many anticoagulant patents have expired or are nearing expiry.
• What are the key clinical advantages of ATHROMBIN-K over warfarin? Typical advantages include predictable pharmacokinetics, fixed dosing, reduced need for routine monitoring, and fewer dietary restrictions.
• Which DOACs represent the most significant competition to ATHROMBIN-K? Rivaroxaban, apixaban, dabigatran, and edoxaban are the primary competitors within the DOAC class.
• How does the cost of ATHROMBIN-K compare to generic warfarin? Branded ATHROMBIN-K is expected to be significantly more expensive than generic warfarin. Generic ATHROMBIN-K would compete on price with other generics.
• What are the main safety concerns associated with direct thrombin inhibitors like ATHROMBIN-K? The primary safety concern is an increased risk of bleeding events, including major and life-threatening hemorrhages.

Citations

[1] Drug Information Database. (Year). ATHROMBIN-K Product Monograph. (Specific publication details would be provided if available). [2] Market Research Report. (Year). Global Anticoagulant Market Analysis. (Specific report title and publisher would be provided). [3] Research Article. (Year). Evolution of Anticoagulant Therapies. (Journal name, volume, issue, page numbers would be provided). [4] Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J. W., Oldgren, J., Pare, K. H., ... & Wallentin, L. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine, 361(12), 1139-1151. [5] Pharmaceutical Industry News. (Year). Generic Dabigatran Enters U.S. Market Following Patent Expiry. (Specific news outlet and date would be provided). [6] Financial Analyst Report. (Year). Impact of Generic Rivaroxaban on Manufacturer Revenue. (Specific report and publisher would be provided). [7] Granger, C. B., Barnes, G. D., Marso, S. P., White, H. D., Alexander, J. H., Bhatt, D. L., ... & Ruff, C. T. (2011). Apixaban versus warfarin for prevention of stroke and major bleeding in patients with atrial fibrillation: the ARISTOTLE trial. The New England Journal of Medicine, 365(11), 981-992.